{"ok":true,"entity":{"id":"crispr-therapeutics","name":"CRISPR Therapeutics","entityType":"company","officialName":"CRISPR Therapeutics AG","canonicalName":"CRISPR Therapeutics","displayName":"CRISPR Therapeutics","category":"遺伝子編集治療","shortDescription":"スイスに登記されCRISPR-Cas9を基盤とする遺伝子編集治療を開発する企業。Vertex Pharmaceuticalsとの共同開発・商業化提携（利益と費用を60対40で分担）により、鎌状赤血球症および輸血依存性βサラセミアを対象とする遺伝子編集治療CASGEVYを実用化している。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.crisprtx.com","updatedAt":"2026-08-06T01:18:46.240Z","secondaryClusters":[],"alias":[],"searchKeywords":["遺伝子編集","CRISPR-Cas9","Casgevy","鎌状赤血球症"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-06-001","P-01-002"]}